ClinicalTrials.gg
CompletedNCT02540668Updated Nov 4, 2019Results posted

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

A Phase 1 interventional study of Lanabecestat and Warfarin in Healthy, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-04.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat by measuring international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. Information about any side effects that may occur will also be collected. The study will last about 5 weeks from the first dose to follow-up for each participant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants: will be sterile (including vasectomy) or agree to use an effective method of and will not donate sperm during the study and for 3 months following the last dose of the product
  • Female participants: women not of

Exclusion criteria

Exclusion Criteria:

  • Have a history of or current, significant ophthalmic disease, as determined by the investigator or ophthalmologist
  • Have vitiligo or any other disorder of skin pigmentation as determined by the investigator or dermatologist
  • Have a history or presence of significant bleeding disorders
  • Have a history of gastrointestinal ulcers with hemorrhage
  • Have a personal or family history of coagulation or bleeding disorders or reasonable suspicion of vascular malformations
  • Self-reported history of increased bleeding from trauma
  • Have a history of major head trauma (with loss of consciousness) within the past year or minor head trauma (without loss of consciousness) within the last 3 months prior to screening
  • History of major surgery within 3 months of screening
  • Planned surgery within 14 days after the last day of dosing
  • (INR)/ Prothrombin Time (PT) or activated partial thromboplastin time above the normal reference range at screening
  • Abnormal Protein S antigen and/or Protein C activity as determined by the investigator
  • History of deep vein thrombosis and/or pulmonary embolism
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Warfarin

    Single oral dose of 15 mg warfarin on Day 1.

    Drug: Warfarin

  • Experimental
    Lanabecestat + Warfarin

    Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.

    Drug: Lanabecestat · Drug: Warfarin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin

    Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22

  2. Pharmacokinetics (PK): Area Under the Concentration Curve 0-∞ (AUC) of Unbound S-Warfarin

    Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound R-Warfarin

    Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22

  2. Pharmacokinetics (PK): Area Under The Concentration Curve 0-∞(AUC) of Unbound R-Warfarin

    Time frame: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96,120, and 144 hours after administration of warfarin on Days 1 and 22

  3. Pharmacodynamics (PD): Area Under the International Normalized Ratio (INR) Versus Time Curve (AUCINR) of Warfarin

    Time frame: Predose, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22

  4. Pharmacodynamics (PD): Maximum Observed INR Response (INRmax) of Warfarin

    Time frame: Predose, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22

07

Results

Posted Mar 25, 2019

Participant flow

Period 1 - Warfarin Single Dose
Participant flow — Period 1 - Warfarin Single Dose
MilestoneWarfarinLY3314814 + Warfarin
Started150
Received at least one dose of study drug150
Completed150
Not completed00
Period 2 - LY3314814 and Warfarin
Participant flow — Period 2 - LY3314814 and Warfarin
MilestoneWarfarinLY3314814 + Warfarin
Started015
Completed014
Not completed01
Withdrew: Physician decision01

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin
Time frame:
Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin
nanogram per milliliter (ng/mL)WarfarinLY3314814 + Warfarin
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin3.50 ± 123.73 ± 14
PrimaryPharmacokinetics (PK): Area Under the Concentration Curve 0-∞ (AUC) of Unbound S-Warfarin
Time frame:
Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Reported as:
Geometric mean · nanogram * hour per milliliter(ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Curve 0-∞ (AUC) of Unbound S-Warfarin
nanogram * hour per milliliter(ng*h/mL)WarfarinLY3314814 + Warfarin
Pharmacokinetics (PK): Area Under the Concentration Curve 0-∞ (AUC) of Unbound S-Warfarin108 ± 18123 ± 19
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound R-Warfarin
Time frame:
Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound R-Warfarin
ng/mLWarfarinLY3314814 + Warfarin
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound R-Warfarin4.45 ± 114.80 ± 14
SecondaryPharmacokinetics (PK): Area Under The Concentration Curve 0-∞(AUC) of Unbound R-Warfarin
Time frame:
Predose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96,120, and 144 hours after administration of warfarin on Days 1 and 22
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics (PK): Area Under The Concentration Curve 0-∞(AUC) of Unbound R-Warfarin
ng*h/mLWarfarinLY3314814 + Warfarin
Pharmacokinetics (PK): Area Under The Concentration Curve 0-∞(AUC) of Unbound R-Warfarin262 ± 18296 ± 18
SecondaryPharmacodynamics (PD): Area Under the International Normalized Ratio (INR) Versus Time Curve (AUCINR) of Warfarin
Time frame:
Predose, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Reported as:
Geometric mean · ng*h/mL
Pharmacodynamics (PD): Area Under the International Normalized Ratio (INR) Versus Time Curve (AUCINR) of Warfarin
ng*h/mLWarfarinLY3314814 + Warfarin
Pharmacodynamics (PD): Area Under the International Normalized Ratio (INR) Versus Time Curve (AUCINR) of Warfarin160 ± 9158 ± 6
SecondaryPharmacodynamics (PD): Maximum Observed INR Response (INRmax) of Warfarin
Time frame:
Predose, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours after administration of warfarin on Days 1 and 22
Reported as:
Geometric mean · ng/mL
Pharmacodynamics (PD): Maximum Observed INR Response (INRmax) of Warfarin
ng/mLWarfarinLY3314814 + Warfarin
Pharmacodynamics (PD): Maximum Observed INR Response (INRmax) of Warfarin1.29 ± 181.26 ± 12

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Warfarin—0/15 (0%)1/15 (6.7%)
LY3314814—0/15 (0%)1/15 (6.7%)
LY3314814 + Warfarin—0/15 (0%)1/15 (6.7%)
Most frequent other events
Most frequent other events
EventWarfarinLY3314814LY3314814 + Warfarin
Retinal haemorrhageEye disorders0/150/151/15
Abdominal pain upperGastrointestinal disorders1/150/150/15
EpistaxisRespiratory, thoracic and mediastinal disorders0/151/150/15

Baseline characteristics

Participants who received one dose of study drug.

Age, Continuous
Age, Continuous(years)Overall
Mean42.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female0
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino1
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White9
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall
United States15
08

Study locations

1 site
  • Covance Clinical Research Inc
    Evansville, Indiana 47710, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Jan 2016, 4 months.

Results were first posted in Mar 2019, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 4, 2015
StartActual
Sep 30, 2015
Primary completionActual
Jan 31, 2016
CompletionActual
Jan 31, 2016
Results first posted
Mar 25, 2019
Last update
Nov 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02540668
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 4, 2015
Start date
Sep 30, 2015
Primary completion
Jan 31, 2016
Completion
Jan 31, 2016
Results posted
Mar 25, 2019
Last update
Nov 4, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lanabecestat · Warfarin

Start the discussion